Weil has advised Ardian in relation to the approximately €700 million financing of the acquisition of Neopharmed Gentili, an Italian specialist in therapeutic drugs, in partnership with NB Renaissance. Together Ardian and NB Renaissance will hold a majority stake on an equal basis.
Neopharmed was previously controlled by Ardian and owned by Mediolanum Farmaceutica Group, and Mediolanum will maintain a significant minority stake in the company.
The Weil team that advised Ardian was led by Banking & Finance partner Tom Richards and included counsel Michael McDonald and associate Dimeji Ademiju.
Weil worked in close partnership with Italian counsel Gattai Minoli Partners, whose team was led by Lorenzo Vernetti and included Federico Tropeano, Valentina Calò and Davide Stracquadanio.